Lipofundin Mct/Lct (Soya-Bean Oil Refined, Triglycerides, Medium Chain)

Soybean oil supplies long‑chain triglycerides that are hydrolyzed to free fatty acids and glycerol. These are rapidly oxidized for energy and incorporated into cell membranes, delivering essential fatty acids required for cellular function and tissue repair during intravenous nutrition.

The prescribed dose is individualized by the treating clinician based on the patient’s caloric requirements, weight, metabolic status, and serum triglyceride levels. No fixed regimen is provided; dosing is adjusted to meet specific nutritional goals.

Safety data in pregnancy and lactation are limited. Use is generally reserved for situations where the nutritional benefit outweighs potential risks, and the decision should be made by the prescribing physician after careful assessment.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Lipofundin Mct/Lct combines soybean oil (long‑chain) with medium‑chain triglycerides, offering a balanced fatty‑acid profile and faster oxidation of MCTs. Compared with pure soybean‑oil emulsions, it may result in lower serum triglyceride spikes and provides additional energy from MCTs, which can be advantageous in critically ill patients.

The emulsion must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the container in its original packaging until use to maintain sterility and product integrity.

It is administered intravenously, typically as a continuous infusion or intermittent infusion mixed with compatible parenteral nutrition solutions. Administration set‑up follows aseptic technique, and infusion rates are adjusted according to the prescribed caloric and lipid goals.

Serious adverse events include fat overload syndrome, severe hypertriglyceridaemia, anaphylactic reactions, pulmonary embolism from lipid particles, and significant hepatic dysfunction. Early detection of respiratory distress, unexplained fever, or rapid rise in triglyceride levels is essential.

Patients with known hypersensitivity to soybean oil, egg phospholipids, or any component of the emulsion should avoid it. It is also contraindicated in individuals with severe hypertriglyceridaemia, uncontrolled sepsis, or those receiving incompatible lipid‑containing infusions that could cause excess lipid load.